Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences.
High expectations have been put into new/atypical neuroleptics for the treatment of schizophrenia: the higher extrapyramidal-motor tolerability and better efficacy in treating negative symptoms supposedly result in a more favourable influencing of the overall course of the disease and in a higher quality of life for the patients. This article will report about the state of evaluation and therapeutic advantages of new/atypical neuroleptics, and thereby deal with problems of definition and methodology. It also describes differences in the unwanted adverse events profile of the different new/atypical antipsychotics.
Möller
H J
HJ
Psychiatric Hospital, Ludwig-Maximilian-University, Munich, Germany. hans-juergen.moeller@psy.med.uni-muenchen.de
D000208:Acute Disease; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000145:classification* / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D006801:Humans; D016202:N-Methylaspartate / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy*; D012701:Serotonin / Q000378:metabolism
D014150:Antipsychotic Agents; D012701:Serotonin; D016202:N-Methylaspartate